Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act

BIOTIE THERAPIES CORP.    STOCK EXCHANGE RELEASE 2 February 2011 at 3.45 p.m.

Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act

Biotie Therapies Corp. ("Company" or "Biotie") has gained knowledge of the
notifications regarding changes in holdings in accordance with Chapter 2,
Section 9 of the Finnish Securities Markets Act, described below.

The notifications received by the Company concern the changes in holdings in the
Company of UCB S.A., 5AM Partners LLC (through 5AM Ventures LLC and 5AM Co-
Investors LLC), Novo A/S as well as Abingworth Manangement Limited (through
Abingworth Bioventures IV LP and Abingworth Bioventures IV Executives LP).

The mentioned parties are parties to a Combination Agreement entered into on 10
January 2011 among the Company, Synosia Therapeutics Holding AG ("Synosia") as
well as Synosia's shareholders and warrant holders, described in more detail in
a stock exchange release issued on 11 January 2011. As described in detail in
Biotie's stock exchange release issued on 2 February 2011, Biotie's
Extraordinary General Meeting has on 1 February 2011 passed resolutions
necessary for the completion of the transaction and the other prerequisites for
the completion of the transaction have been fulfilled, and the Company has
issued 161,448,371 shares to the shareholders and warrant holders of Synosia as
consideration for the entire issued share capital and outstanding warrants of
Synosia (the "Transaction"). In connection with the Transaction, the Company
issued 14,912,155 to Synosia to be held in treasury and used to satisfy future
potential exercise of Synosia's options. The new shares shall be registered on
or about 3 February 2011.

In the Transaction new shares in the Company were issued to the notifying
parties, and the resulting holdings of shares and votes in the Company of the
notifying parties after the completion of the Transaction would be as follows,
and the notifying parties are entitled to use the rights attached to the new
shares upon their registration with the Finnish Trade Register (on or about 3
February 2011):

Name              Number of shares  Voting rights     Share of      Share of
                  to be received    shares to be      share capital voting
                  subject to        received subject  (%)           rights (%)
                  completion of     to completion of
                  Transaction       Transaction

UCB S.A           31,486,996        31,486,996        8.94          9.76

5AM Ventures LLC  14,590,660        14,590,660        4.14          4.52
(controlled by
5AM Partners LLC)

5AM Co-Investors  2,070,363         2,070,363         0.59          0.64
LLC (controlled
by 5AM Partners
LLC)

5AM Partners LLC  16,661,023        16,661,023        4.73          5.16
(through 5AM
Ventures LLC and
5AM Co-Investors
LLC) in total

Novo A/S          26,158,853        26,158,853        7.42          8.11

Abingworth        16,551,331        16,551,331        4.70          5.13
Bioventures IV LP
(controlled by
Abingworth
Management
Limited)

Abingworth        141,927           141,927           0.04          0.04
Bioventures IV
Executives LP
(controlled by
Abingworth
Management
Limited)

Abingworth        16,693,258        16,693,258        4.74          5.17
Management
Limited (through
Abingworth
Bioventures IV LP
and Abingworth
Bioventures IV
Executives LP) in
total



The number of voting rights and percentages presented above are calculated based
on number of shares and voting rights obtained upon completion of the
Transaction taking into account the treasury shares held by the Company on the
date of the notification.

On the date hereof, the registered number of shares in Biotie Therapies Corp. is
176,003,931. Of these shares 14,747,084 are held by the Company and the number
of outstanding registered shares and voting rights attached to such shares
amounts thus to 161,256,847. Subsequent to the registration of the new shares to
be issued in connection with the Transaction, the aggregate number of Biotie
shares will be 352,364,457. Of these shares, 29,659,239 will be held by the
Company or its group companies.

Turku, 2 February 2011

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900
e-mail:virve.nurmi@biotie.com

DISTRIBUTION
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com


[HUG#1484695]